Hui Zhou

Stories

Innovent presents first clinical data for first-in-class EGFR/B7H3 bispecific ADC

Leading IBI3001 development and the company's AD C pipeline

Innovent Biologics presented the first clinical data for IBI3001, an EGFR/B7H3 bispecific antibody-drug conjugate (ADC, a targeted drug carrying a chemotherapy payload), at the 2026 European Society for Medical Oncology (ESMO) congress. Of 57 patients who received the drug, 78.9% had two or more prior treatment lines. Among 53 patients evaluable for response, 30.2% responded and 88.7% had disease control.

Updated Oct 26

Innovent's IBI354 HER2 ADC posts high response rate in first-line breast cancer trial

New Capabilities

Oversees IBI354 Phase 3 development including HeriCare-Breast01 and HeriCare-Ovarian01

Innovent presented Phase 2 results at the European Society for Medical Oncology (ESMO) congress on October 24. The data show its experimental HER2-targeting antibody-drug conjugate (ADC), IBI354, plus pertuzumab produced a 95% confirmed response rate in patients with unresectable, locally advanced or metastatic HER2-positive breast cancer. That is 19 of 20 patients, and none developed interstitial lung disease (ILD), a lung inflammation that is a known risk with trastuzumab deruxtecan (Enhertu).

Updated Oct 26

First CLDN18.2 antibody-drug conjugate reaches regulatory review for gastric cancer

New Capabilities

As of June 2026: Leading the drug's development program

Advanced gastric cancer that returns after treatment usually kills within about six months. On June 4, 2026, Chinese biotech Innovent Biologics said its drug had slowed that clock in a late-stage trial.

Updated Jun 4

Notable Quotes

"By targeting two tumor-associated antigens, this approach is designed to improve tumor-targeting specificity and reduce off-target toxicity, while covering a broader population of patients who may benefit." — Dr. Hui Zhou, on IBI3001's rationale

from Innovent presents first clinical data for first-in-class EGFR/B7H3 bispecific ADC · Updated Oct 26

We have initiated a Phase 3 study evaluating IBI354 as a first-line treatment for HER2-positive advanced breast cancer, with additional Phase 3 studies being planned.

from Innovent's IBI354 HER2 ADC posts high response rate in first-line breast cancer trial · Updated Oct 26

Patients with advanced gastric cancer generally have poor prognosis after initial treatment, with median survival around six months.

from First CLDN18.2 antibody-drug conjugate reaches regulatory review for gastric cancer · Updated Jun 4